Exercise Intervention Study for Pancreatic Cancer Patients (SUPPORT)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01977066 |
Recruitment Status :
Completed
First Posted : November 6, 2013
Last Update Posted : February 27, 2017
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Pancreatic Cancer | Behavioral: Six months supervised resistance training Behavioral: Six months home-based exercise training | Not Applicable |
The randomized-controlled balanced-parallel-group trial included 65 adult pancreatic cancer patients (stage I-IV) from the University Surgery Clinic in Heidelberg. The study compared two specific exercise interventions and one standard care control arm. The intervention programs were (1) a 6-month supervised moderate-to-high-intensity, progressive resistance training, and (2) a 6-month home-based exercise training. Thus, the two interventions differed primarily by the intensity and mode-of-administration of the intervention. Both interventions started at the earliest 8 weeks after surgery to allow for wound healing until Maximum 12 months after the surgery. The supervised progressive training started with only moderate-intensity training during the first 4 weeks. Only patients without comorbidities that preclude participation in the intervention arms (e.g. severe pain, heart insufficiency, reduced standing or walking ability) were eligible.
The primary objective is to compare the effects of the different interventions on physical functioning, measured as change from baseline to 6 months. Additional endpoints are overall quality of life, fatigue, endurance, and strength performance, adherence to the interventions, discontinuation of adjuvant therapy, body weight and composition, disease progression, overall and progression-free survival. All outcomes has been assessed every 3 months for a minimum follow-up period of 12 months.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 65 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Supportive Care |
Official Title: | SUPPORT - Study Supervised Progressive Resistance Training for Pancreatic Cancer Patients: a Randomized Controlled Intervention Trial |
Study Start Date : | November 2013 |
Actual Primary Completion Date : | June 2016 |
Actual Study Completion Date : | December 2016 |

Arm | Intervention/treatment |
---|---|
Experimental: Six months supervised exercise training |
Behavioral: Six months supervised resistance training
progressive resistance training (2x/week), starting at the earliest 8 weeks after surgery until maximum 12 months after the surgery with only low-to-moderate-intensity training during the first 4 weeks. |
Experimental: Six months home-based exercise training |
Behavioral: Six months home-based exercise training
Home-based exercise training (2x/week) with initial counseling and weekly telephone contact starting at the earliest 8 weeks after surgery until maximum 12 months after the surgery. |
No Intervention: Control group |
- Physical functioning score, as assessed by the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ) EORTC QLQ-C30 [ Time Frame: Change from baseline to end of intervention (after 6 months) ]
- Overall quality of life from EORTC QLQ-C30 and the specific module for pancreatic cancer(QLQ-PAN26) [ Time Frame: change from Baseline to end of intervention (6 months) ]
- Fatigue (Multidimensional Fatigue Inventory (MFI)) [ Time Frame: change from baseline to end of intervention (6 months) ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Pancreatic cancer patients (stage I-IV)
- Patients ≥ 18 years of age
- Resection performed at the University Clinic of Heidelberg
- Sufficient German language skills
- Signed informed consent
Exclusion Criteria:
• Presence of comorbidities that preclude participation in the intervention arms (e.g. severe pain, heart insufficiency, reduced standing or walking ability)

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01977066
Germany | |
German Cancer Research Center | |
Heidelberg, Germany, D-69120 |
Principal Investigator: | Karen G Steindorf, Prof. Dr. | German Cancer Research Center (DKFZ)/ German National Center for Tumor Diseases (NCT) |
Responsible Party: | German Cancer Research Center |
ClinicalTrials.gov Identifier: | NCT01977066 |
Other Study ID Numbers: |
SUPPORT |
First Posted: | November 6, 2013 Key Record Dates |
Last Update Posted: | February 27, 2017 |
Last Verified: | February 2017 |
pancreatic cancer exercise training quality of life physical functioning |
Pancreatic Neoplasms Digestive System Neoplasms Neoplasms by Site Neoplasms |
Endocrine Gland Neoplasms Digestive System Diseases Pancreatic Diseases Endocrine System Diseases |